Cybin Inc. (CYBN)
NYSEAMERICAN: CYBN · Real-Time Price · USD
7.60
-0.03 (-0.39%)
At close: Aug 13, 2025, 4:00 PM
7.50
-0.10 (-1.32%)
Pre-market: Aug 14, 2025, 9:03 AM EDT
Heartland Financial USA Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
50
Market Cap
175.05M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | 864.00K | - | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CYBN News
- 16 hours ago - Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results - Business Wire
- 7 days ago - Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
- 8 days ago - Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference - Business Wire
- 4 weeks ago - Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
- 6 weeks ago - REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures - Business Wire
- 6 weeks ago - Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights - Business Wire
- 6 weeks ago - Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures - Business Wire
- 2 months ago - Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics - Business Wire